Skip to search formSkip to main contentSkip to account menu

tipifarnib

Known as: (+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 2 (1H))-quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-,(+)- 
A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an… 
National Institutes of Health

Related topics

Related topics

11 relations
Angiogenesis InhibitionInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of Apoptosis

Broader (2)

Antineoplastic AgentsQuinolones

Narrower (2)

R115777Zarnestra

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and…
BACKGROUND RAS is dysregulated in neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PNs). The activity of… 
Highly Cited
2014
Highly Cited
2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Pirfenidone, an oral anti‐inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti‐tumor… 
Highly Cited
2011
Highly Cited
2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated…
PURPOSE Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET) kinase pathways are important in thyroid cancer. We tested… 
Highly Cited
2008
Highly Cited
2008
Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.
Highly Cited
2006
Highly Cited
2006
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
PURPOSE This pediatric phase I trial of tipifarnib determined the maximum-tolerated dose (MTD), pharmacokinetics, and… 
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Review
2006
Review
2006
Tipifarnib: farnesyl transferase inhibition at a crossroads
Tipifarnib is an oral nonpeptidomimetic farnesyl transferase inhibitor developed to inhibit a variety of farnesylated targets… 
Highly Cited
2004
Highly Cited
2004
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple…
Patients with multiple myeloma (MM) with mutated RAS are less likely to respond to chemotherapy and have a shortened survival… 
Highly Cited
2004
Highly Cited
2004
Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
The search for new cancer therapeutics has identified protein farnesyltransferase (FTase) as a promising drug target. This enzyme… 
Review
2002
Review
2002
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)